Decitabine enhances targeting of AML cells by CD34

Authors :: Jeannette, Cany
Mieke W H, Roeven
Janneke S, Hoogstad-van Evert
Willemijn, Hobo
Frans, Maas
Rosalia, Franco Fernandez
Nicole M A, Blijlevens
Walter J, van der Velden
Gerwin, Huls
Joop H, Jansen
Nicolaas P M, Schaap
Harry, Dolstra
Source :: Blood. 131(2)
Publication Year :: 2017
Abstract: Combining natural killer (NK) cell adoptive transfer with hypomethylating agents (HMAs) is an attractive therapeutic approach for patients with acute myeloid leukemia (AML). However, data regarding the impact of HMAs on NK cell functionality are mostly derived from in vitro studies with high nonclinical relevant drug concentrations. In the present study, we report a comparative study of azacitidine (AZA) and decitabine (DAC) in combination with allogeneic NK cells generated from CD34